CN1657082A - Oral Chinese medicinal composition for treating virus myocarditis - Google Patents
Oral Chinese medicinal composition for treating virus myocarditis Download PDFInfo
- Publication number
- CN1657082A CN1657082A CN 200410035647 CN200410035647A CN1657082A CN 1657082 A CN1657082 A CN 1657082A CN 200410035647 CN200410035647 CN 200410035647 CN 200410035647 A CN200410035647 A CN 200410035647A CN 1657082 A CN1657082 A CN 1657082A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- treatment
- viral myocarditis
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims description 14
- 241000700605 Viruses Species 0.000 title description 9
- 208000009525 Myocarditis Diseases 0.000 title description 5
- 206010047470 viral myocarditis Diseases 0.000 claims abstract description 31
- 239000003814 drug Substances 0.000 claims description 54
- 241000628997 Flos Species 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 21
- 239000009636 Huang Qi Substances 0.000 claims description 14
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 241000245240 Lonicera Species 0.000 claims description 2
- 241000219780 Pueraria Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 241001180876 Saposhnikovia Species 0.000 claims description 2
- 239000000463 material Substances 0.000 abstract description 2
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 230000000694 effects Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 208000011580 syndromic disease Diseases 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 230000001502 supplementing effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229940039009 isoproterenol Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 206010064550 Myocarditis post infection Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000007613 Shoulder Pain Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001595 contractor effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000007529 rheumatic myocarditis Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008460 toxic myocarditis Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An orally taken Chinese medicing for treating viral myocarditis is prepared from 7 Chinese-medicinal materials including astragalus root, Chinese angelica roto, white peony root, Chuan-xiong rhizome, etc.
Description
Technical field
The present invention relates to a kind of oral Chinese medicine compositions, specifically relate to a kind of oral Chinese medicine compositions for the treatment of viral myocarditis.
Background technology
The M ﹠ M of cardiovascular system diseases is first of each systemic disease.Viral myocarditis is that it is seriously endangering human beings'health, particularly teenager, child and postadolescent by the acute or chronic inflammatory disease of the caused cardiac muscle of viral infection.Because antibiotic extensive use, the sickness rate of rheumatic myocarditis obviously descends, and the sickness rate of viral myocarditis obviously rises, and sickness rate increases nearly ten times over past ten years, has become one of commonly encountered diseases of cardiovascular system.Case fatality rate 2.8%～12%, 5% exists cicatrix due to the myocarditis, and 15%～20% electrocardiogram still had in 5 years unusually, and 5% develops into cardiomyopathy.Mainly show as cardiopalmus, chest pain, breathe hard, weak etc., course of disease weak point person several months, elder several years even decades, sequela or the part often left in various degree transfer cardiomyopathy, the serious harm people's health to.
Doctor trained in Western medicine is many to support trophotherapy and symptomatic treatment to the treatment of this disease at present, and its specific medicament is less.Modern medicine thinks that primary disease is by the viral infection myocardial cell, and relevant with the disorder of body's immunity, symptoms such as myocardial ischemia, necrosis and cardiac arrhythmia occur.Clinical immunosuppressant and the regulator of focusing on, non-steroid antibiotic medicine, antiviral agents and composite treatment thereof, but curative effect is unsatisfactory.
Drug therapy to viral myocarditis, Recent study is a lot, particularly traditional Chinese medical science medicine has shown bigger advantage in the treatment viral myocarditis, though the Chinese medicine of present existing treatment viral myocarditis has been obtained certain effect, but also remain in some shortcomings,, dosage form not good enough as curative effect falls behind, takes inconvenience etc.
Summary of the invention
Purpose of the present invention just is to avoid and overcomes the shortcoming and defect of prior art and a kind of Chinese medicine composition for the treatment of viral myocarditis is provided, and this Chinese medicine composition is evident in efficacy, taking convenience, short treating period, no obvious sequela.
A kind of Chinese medicine composition for the treatment of viral myocarditis involved in the present invention, it mainly is to be made by following bulk drugs: the Radix Astragali, Radix Ophiopogonis, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Flos Carthami.
For reaching better therapeutic, medicine of the present invention is also combined with Radix Puerariae, Radix Saposhnikoviae, Fructus Aurantii, Flos Lonicerae, Folium Isatidis.
For obtaining best curative effect, medicine of the present invention also can add Radix Glycyrrhizae on the basis of said medicine.
Viral myocarditis relates to categories such as the traditional Chinese medical science " cardiopalmus ", " palpitation with a distress feeling ", " thoracic obstruction ", the Chinese medicine viral myocarditis has special advantages, the inventor is according to for many years the treatment experience of this disease and experimentation being confirmed, holding concurrently with the detoxifcation with supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind is method, draft with the Radix Astragali, Radix Ophiopogonis, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Flos Carthami, etc. kinds of traditional Chinese medicines, be processed into granule through science, treatment is with syndrome of deficiency of both qi and yin or to hold the stasis of blood under the arm be that the viral myocarditis effect of main clinical manifestation is preferable.
The present invention is through clinical verification for many years and through repeatedly the zoopery confirmation is evident in efficacy and definite.Chinese medicine is thought evil drug-pedlar's heart, decreases that cloudy to feel frustrated be this sick pathogenesis key.So commonly clinically have palpitation, breathe hard, disease such as vexed the time, again with the performance of breast shoulder pain, according to deficiency and excess of " interior warp " " deficiency syndrome should be treated by tonifying method, sthenia syndrome requiring purgation " and the principle of controlling, be to cause a disease originally in the treatment at this medicine deficiency of both QI and YIN, blood stasis is in the target pathogenic characteristic of the heart for causing a disease, adopt supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling is main prescription, and the Radix Astragali is monarch in the side, tonification vigour rouses oneself heart-yang; Minister reaches the effect of replenishing YIN and blood, calming heart and tranquilizing mind, blood circulation promoting and blood stasis dispelling with Radix Ophiopogonis, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Flos Carthami, cooperates the effect of the capable supplementing QI and nourishing YIN blood stasis dispelling of monarch drug.But wherein help the breast sun of holding back with Radix Puerariae, Radix Saposhnikoviae, Fructus Aurantii Xuan Changmeng, QI invigorating Gu Wei, harmonizing the functional activities of vital QI, be equipped with Flos Lonicerae, Folium Isatidis heat-clearing and toxic substances removing, remove the residual scorchingly hot heresy of epidemic disease of not using up, make with the invigorating middle warmer of Radix Glycyrrhizae QI invigorating, relieving spasm to stop pain, and the energy coordinating the actions of various ingredients in a prescription is played supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling, calming heart and tranquilizing mind altogether, is held concurrently with the effect of detoxifcation.The present invention selects the above-mentioned raw materials medicine to make up, and makes each efficacy of drugs produce synergism, thereby effectively treats hypertension.
The consumption of its drug component of oral Chinese medicine compositions of the present invention is also groped to sum up to draw through the inventor in a large number, and each amounts of components is for all to have better curative effect in the following weight parts scope:
Radix Astragali 20-40 part, Radix Ophiopogonis 15-30 part, Radix Angelicae Sinensis 15-30 part, Radix Paeoniae Alba 15-30 part, Rhizoma Chuanxiong 5-15 part, Radix Salviae Miltiorrhizae 5-15 part, Flos Carthami 3-10 part.
Preferred weight part scope is: Radix Astragali 30-35 part, Radix Ophiopogonis 20-25 part, Radix Angelicae Sinensis 20-25 part, Radix Paeoniae Alba 20-25 part, Rhizoma Chuanxiong 10-15 part, Radix Salviae Miltiorrhizae 10-15 part, Flos Carthami 5-8 part.
Drug component weight portion of the present invention can also be Radix Astragali 20-40 part, Radix Ophiopogonis 15-30 part, Radix Angelicae Sinensis 15-30 part, Radix Paeoniae Alba 15-30 part, Rhizoma Chuanxiong 5-15 part, Radix Salviae Miltiorrhizae 5-15 part, Flos Carthami 3-10 part, Radix Puerariae 5-15 part, Radix Saposhnikoviae 5-15 part, Fructus Aurantii 5-15 part, Flos Lonicerae 15-30 part, Folium Isatidis 15-30 part, Radix Glycyrrhizae 5-15 part.
Medicine of the present invention further the weight portion of each component be Radix Astragali 30-35 part, Radix Ophiopogonis 20-25 part, Radix Angelicae Sinensis 20-25 part, Radix Paeoniae Alba 20-25 part, Rhizoma Chuanxiong 10-15 part, Radix Salviae Miltiorrhizae 10-15 part, Flos Carthami 5-8 part, Radix Puerariae 10-15 part, Radix Saposhnikoviae 10-15 part, Fructus Aurantii 10-15 part, Flos Lonicerae 20-25 part, Folium Isatidis 20-25 part, Radix Glycyrrhizae 10-15 part.
The weight portion of each crude drug that the present invention more optimizes is 33 parts of the Radixs Astragali, 22 parts of Radix Ophiopogonis, 22 parts of Radix Angelicae Sinensis, 22 parts of the Radix Paeoniae Albas, 11 parts of Rhizoma Chuanxiongs, 11 parts of Radix Salviae Miltiorrhizaes, 5.6 parts on Flos Carthami, 11 parts of Radix Puerariaes, 11 parts of Radix Saposhnikoviaes, 11 parts of Fructus Aurantiis, 22 parts of Flos Loniceraes, 22 parts of Folium Isatidiss, 11 parts in Radix Glycyrrhizae.
Medicine of the present invention can adopt the conventional method of Chinese medicine preparation to be prepared into any conventional oral preparations, as pill, powder, tablet, capsule, oral liquid etc.
In sum, this reasonable recipe, curative effect are reliable, are effective prescriptions of treatment viral myocarditis.Supplementing QI and nourishing YIN of the present invention, promoting blood circulation and detoxication.Be used for the viral myocarditis course of disease and surpass one month acute stage light-duty and convalescent period, the light medium-sized genus deficiency of both QI and YIN of lag phase and have the stagnant heat card concurrently, disease sees cardiopalmus, breathes hard, uncomfortable in chest or chest pain, weak, insomnia, dreaminess person.
The specific embodiment
By the following examples, the beneficial effect of medicine of the present invention is further set forth in pharmacodynamics test and clinical trial.
Embodiment:
Prescription: Radix Astragali 330g, Radix Ophiopogonis 220g, Radix Angelicae Sinensis 220g, Radix Paeoniae Alba 220g, Rhizoma Chuanxiong 110g, Radix Salviae Miltiorrhizae 110g, Flos Carthami 56g, Flos Lonicerae 220g, Folium Isatidis 220g, Radix Puerariae 110g, Radix Saposhnikoviae 110g, Fructus Aurantii 110g, Radix Glycyrrhizae 110g
Method for making: by technical scheme of the present invention, Radix Angelicae Sinensis, Rhizoma Chuanxiong, Radix Saposhnikoviae, Fructus Aurantii are added water extracted volatile oil 4 hours for 4 times, aqueous solution filters, and medicinal residues add 7 times in water, decoct 1 hour, and collecting decoction is concentrated into relative density and is 1.15 (50 ℃), and is standby.The Radix Astragali, Radix Salviae Miltiorrhizae, Flos Lonicerae, Radix Puerariae add 5,4,3 times of amount alcohol successively with 60% alcohol reflux, and 2 hours for the first time, for the second time, each 1.5 hours for the third time, merge extractive liquid, filtered filtrate for later use.The five tastes and above-mentioned two kinds of medicinal residues merging such as all the other Radix Ophiopogonis decoct with water three times, add 8 successively, 7,6, times water gaging, 2 hours for the first time, for the second time, each 1 hour for the third time, collecting decoction, filter, it is 1.15～1.20 (50 ℃) that filtrate is concentrated into relative density, and the gained concentrated solution merges during with said extracted volatile oil, mixing, put coldly, add ethanol and make and contain alcohol amount and reach 60%, standing over night, filter, precipitation is stirred with a small amount of 60% ethanol and is washed once, filters, and alcohol extracts such as the filtrate and the above-mentioned Radix Astragali merge, reclaim ethanol, being concentrated into relative density is 1.22～1.24 (50 ℃), add appropriate amount of auxiliary materials (press adjuvant: extractum=1: 1), spray granulation, volatile oil is diluted with small amount of ethanol, be sprayed in the dried granule covered and enclosed 4 hours, cold drying equably, granulate is made 1000g promptly.
Function cures mainly: supplementing QI and nourishing YIN, promoting blood circulation and detoxication.Be used for the viral myocarditis course of disease and surpass one month acute stage light-duty and convalescent period, the light medium-sized genus deficiency of both QI and YIN of lag phase and have the stagnant heat card concurrently, disease sees cardiopalmus, breathes hard, uncomfortable in chest or chest pain, weak, insomnia, dreaminess person.
Usage and consumption: take after mixing it with water, 3 years old, one time 1/4 bag, 4-6 year, one time 1/2 bag, 7-10 year, one time 3/4 bag, more than 10 years old and the adult, one time 1 bag, 2 times on the one, one after each meal.
Specification: every packed 15g.
Usage and dosage: one time 3,3 times on the one.
Pharmacodynamics test:
1. external anti-CB
3The virus result of the test shows: this product is to infecting CB
3The rat neonatal rat myocardial cell and the Vero cell of virus have significant protective effect, can stop CB
3The virus absorption surface enters cell and produces direct deactivation.The medication group can obviously reduce the lesion degree of cultured cell, reduces the myocardial cell virus titer that infects, and is good dose-effect relationship.
2. anti-CB in the body
3The virus result of the test shows: this product is to CB
3Virogenetic mice viral myocarditis has significant protective effect, can improve neutralizing antibody concentration in the mice body, obviously suppresses Vero necrocytosis rate, and it suppresses percentage rate can reach 400%, and obviously reduces administration group mice serum virus titer.Pathological examination shows that the pathological change of administration group mouse cardiac muscle cell is significantly less than the virus control group, and prompting has therapeutical effect to viral myocarditis.
3. the test of open chest anesthetized cardiac hemodynamics of dogs shows: this product can obviously reduce arteriotony and total peripheral resistance; Reduce coronary resistance, increase coronary flow; Reduce left indoor pressure, left chamber EDP, ± dp/dtmax; Increase cardiac output, cardiac index and SI; And reduce myocardium coefficient of oxygen utilization and oxygen consumption index.Heart rate and electrocardiogram there is not obvious shadow noon.In sum, this medicine can reduce load before and after the heart, reduces cardiac work, and increases the blood supply of cardiac muscle oxygen supply, reduces myocardial oxygen consumption, though weaken myocardial contraction, does not reduce cardiac output, and the heart of viral myocarditis is had certain protective role.
4. the test of Acute Myocardial Ischemia in Rats that anti-isoproterenol brings out shows: the ECG change and the pathological change of the Acute Myocardial Ischemia in Rats that this product can obviously be resisted isoproterenol and brought out.
5. the test of anti-pituitrin brought out myocardial ischemia shows: the ECG change of the Acute Myocardial Ischemia in Rats that this product can obviously be resisted pituitrin and brought out.
6. white mice normal pressure hypoxia endurance test shows: this product can obviously improve the hypoxia-bearing capability under the normal pressure, prolongs the mice time-to-live.
7. the arrhythmia test confirms: this product can obviously be resisted the ECG change of the rat ventricular that is brought out by barium chloride, and its suppression ratio can reach 78%, and heart is had good protective action.
Therefore, can think that from results of pharmacodynamic test this product has anti-CB
3Virus, protecting myocardial cell increases the blood supply oxygen supply of cardiac muscle, improves myocardial ischemia and antiarrhythmic effect, is the medicine of a comparatively ideal treatment viral myocarditis, and the result of clinical trial has also further proved its curative effect.
The result of the test of acute toxicity and long term toxicity
Acute toxicity test: give this product medicated powder by the disposable filling stomach of white mice, maximum concentration 35%, the maximum gastric capacity 0.4ml/10g that irritates, dosage 14g/kg (every g medicated powder is equivalent to the 10g crude drug), observed 7 days continuously, do not find any toxic reaction, because of concentration and dosage can't increase, so fail to measure the LD of this medicine
50
Maximum tolerance determination: with maximum concentration, the maximum gastric capacity of irritating, mice lavage administration 3 times, 5 hours at interval, to observe continuously then 7 days, none example is dead.Medicated powder dosage is＞42g/kg. day (every g medicated powder is equivalent to the 10g crude drug), calculate the clinical consumption per day that is equivalent to be grown up by kg body weight 420 times.
Long term toxicity test: whether toxigenicity reacts in order to observe long-term prescription, give rat this product medicated powder respectively and raise clothes, by adult 70 times of clinical consumption per day and 35 times (being 7g/kg/ day and 3.5g/kg/ day), in 8 weeks of successive administration, do not see that behavior, feed, the body weight of rat occurs unusually, with the matched group ratio, routine blood test, hepatic and renal function, all no abnormal change of various important organs, in institute's dosage scope, do not found any toxicity of this product.Acute and chronic toxicity test by animal confirms that this product drug safety scope is bigger, is a kind of safe and reliable compound preparation.
Clinical trial:
Applicant of the present invention to medicine of the present invention carry out at random, double blinding, multicenter contrast clinical trial.Include several 450 examples of the total example of test in, actual finishing observed several 450 examples of example, wherein observes adult's 290 examples, test group 215 examples, matched group 75 examples; Observe child's 160 examples, test group 119 examples, matched group 41 examples.
One, test case standard
(1) include the case standard in:
1. meet the viral myocarditis diagnosis.
2. the state of an illness is limited to light, medium-sized case.
3. acute stage (adopt existing doctor trained in Western medicine routine treatment, acute stages treated is included in after making stable disease in one month), convalescent period, lag phase by stages.
4. 3 years old≤child≤14 years old, the adult was≤45 years old in 14 years old.
5. meet hold concurrently stagnant heat card of traditional Chinese medical science cardiopalmus deficiency of both QI and YIN.
(2) get rid of the case standard:
1. suffer from hyperthyroidism, beta receptor hyperfunctioning and influence other disease of heart, as the rheumatic heart
Myositis, toxic myocarditis, coronary heart disease, connective tissue disease, metabolic disease etc.
2. heavy myocarditis, heart failure, severe arrhythmia, hyperpyrexia etc.
3. gestation or women breast-feeding their children.
4. be associated with serious primary disease such as cerebrovascular, liver, kidney and hemopoietic system, the psychotic.
5. age: child＜3 years old,＞45 years old person is grown up.
(3) reject the case standard:
1. end the experimenter because of irritated or other untoward reaction, be not counted in the row of curative effect of medication statistics, but count among the untoward reaction evaluation.
2. other unprovoked curative effect of medication is former thereby withdraw from the experimenter.
3. all standards of including in that do not meet, not medication in accordance with regulations can't be judged that curative effect or data are not congruent to affect the treatment or safety judgement person.
Two, clinical test results shows:
(1), comprehensive therapeutic effect:
1. adult: viral myocarditis (cardiopalmus deficiency of both QI and YIN hold concurrently stagnant heat) adult patient 290 examples are observed in clinical trial, test group 215 examples wherein, matched group 75 examples.This product is 45.6% to the apparent more rate of the comprehensive therapeutic effect of adult patient, and total effective rate is 85.1; It is 34.7% that the comprehensive treatment of matched group shows the rate of healing, and total effective rate is 74.7%.Both compare, P＜0.05, and there were significant differences.Test group obviously is better than matched group to adult's comprehensive therapeutic effect.
2. child: viral myocarditis (cardiopalmus deficiency of both QI and YIN hold concurrently stagnant heat) child patient 160 examples are observed in clinical trial, test group 119 examples wherein, matched group 41 examples.This product is 49.58% to the apparent more rate of the comprehensive therapeutic effect of child patient, and total effective rate is 90.76%; It is 41.46% that the comprehensive treatment of matched group shows the rate of healing, and total effective rate is 80.49%.Both compare, P＞0.05, no difference of science of statistics.Test group shows the rate of healing and total effective rate is better than matched group.
(2), ECG curative effect:
1. this product improves significantly to adult's resting electrocardiogram, and the resting electrocardiogram effective percentage is 60.00%, and matched group is 52.00%, and both compare, P＞0.05, and no significant difference, test group electrocardiogram effective percentage is better than matched group; To the ventricular premature contraction effect of having clear improvement of being grown up, showing more, rate is: 51.61%, and total effective rate is: 83.87%, matched group shows more rate 43.33%, total effective rate 80.00%, both compare, no difference of science of statistics.Test group is better than matched group to the rate of healing that shows that ambulatory electrocardiogram has.
2. this product improves significantly to child's resting electrocardiogram, and effective percentage is 58.82%, matched group effective percentage 48.78%, and both compare no difference of science of statistics, and test group is better than matched group to the child's electrocardiogram effective percentage; This product also can obviously be improved child's cardiopalmus patient's tcm syndrome, to the effect that also has clear improvement of unusual picture of the tongue and pulse condition, can partly improve patient's unusual sign.
(3), tcm syndrome
1. this product can obviously be improved adult diseases viral myocarditis (cardiopalmus) patient's tcm syndrome, to the effect that also has clear improvement of unusual picture of the tongue and pulse condition, can partly improve patient's unusual sign.Test group tcm syndrome curative effect cure rate is 60.47%, and total effective rate is: 87.44%; Matched group shows more, and rate is: 40.00%, and total effective rate is 77.33%, both contrasts, P＜0.05, test group obviously is better than matched group to the curative effect of adult's tcm syndrome.
2. this product can obviously be improved children virus myocarditis (cardiopalmus) tcm syndrome, and tcm syndrome curative effect cure rate is 63.03%, and total effective rate is: 89.08%; Matched group shows more, and rate is: 58.54%, and total effective rate is 85.37%, both compare no difference of science of statistics.
Clinical test results shows: myocardium recovering particles treatment viral myocarditis is safely and effectively.
Claims (6)
1, a kind of oral Chinese medicine compositions for the treatment of viral myocarditis is characterized in that it mainly is to be made by following bulk drugs: the Radix Astragali, Radix Ophiopogonis, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Flos Carthami.
2, a kind of oral Chinese medicine compositions for the treatment of viral myocarditis according to claim 1, it is characterized in that wherein the weight portion of each crude drug be Radix Astragali 20-40 part, Radix Ophiopogonis 15-30 part, Radix Angelicae Sinensis 15-30 part, Radix Paeoniae Alba 15-30 part, Rhizoma Chuanxiong 5-15 part, Radix Salviae Miltiorrhizae 5-15 part, Flos Carthami 3-10 part.
3, a kind of oral Chinese medicine compositions for the treatment of viral myocarditis according to claim 2, it is characterized in that wherein the weight portion of each crude drug be Radix Astragali 30-35 part, Radix Ophiopogonis 20-25 part, Radix Angelicae Sinensis 20-25 part, Radix Paeoniae Alba 20-25 part, Rhizoma Chuanxiong 10-15 part, Radix Salviae Miltiorrhizae 10-15 part, Flos Carthami 5-8 part.
4, a kind of oral Chinese medicine compositions for the treatment of viral myocarditis according to claim 2 is characterized in that wherein crude drug also has Radix Puerariae 5-15 part, Radix Saposhnikoviae 5-15 part, Fructus Aurantii 5-15 part, Flos Lonicerae 15-30 part, Folium Isatidis 15-30 part, Radix Glycyrrhizae 5-15 part.
5, a kind of oral Chinese medicine compositions for the treatment of viral myocarditis according to claim 4, it is characterized in that wherein the weight portion of each crude drug be Radix Astragali 30-35 part, Radix Ophiopogonis 20-25 part, Radix Angelicae Sinensis 20-25 part, Radix Paeoniae Alba 20-25 part, Rhizoma Chuanxiong 10-15 part, Radix Salviae Miltiorrhizae 10-15 part, Flos Carthami 5-8 part, Radix Puerariae 10-15 part, Radix Saposhnikoviae 10-15 part, Fructus Aurantii 10-15 part, Flos Lonicerae 20-25 part, Folium Isatidis 20-25 part, Radix Glycyrrhizae 10-15 part.
6, a kind of oral Chinese medicine compositions for the treatment of viral myocarditis according to claim 5 is characterized in that wherein the weight portion of each crude drug is 33 parts of the Radixs Astragali, 22 parts of Radix Ophiopogonis, 22 parts of Radix Angelicae Sinensis, 22 parts of the Radix Paeoniae Albas, 11 parts of Rhizoma Chuanxiongs, 11 parts of Radix Salviae Miltiorrhizaes, 5.6 parts on Flos Carthami, 11 parts of Radix Puerariaes, 11 parts of Radix Saposhnikoviaes, 11 parts of Fructus Aurantiis, 22 parts of Flos Loniceraes, 22 parts of Folium Isatidiss, 11 parts in Radix Glycyrrhizae.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100356474A CN1302799C (en) | 2004-09-06 | 2004-09-06 | Oral Chinese medicinal composition for treating virus myocarditis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100356474A CN1302799C (en) | 2004-09-06 | 2004-09-06 | Oral Chinese medicinal composition for treating virus myocarditis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1657082A true CN1657082A (en) | 2005-08-24 |
| CN1302799C CN1302799C (en) | 2007-03-07 |
Family
ID=35006912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100356474A Expired - Lifetime CN1302799C (en) | 2004-09-06 | 2004-09-06 | Oral Chinese medicinal composition for treating virus myocarditis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1302799C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100349597C (en) * | 2005-11-14 | 2007-11-21 | 咸阳步长医药科技发展有限公司 | Chinese medicinal preparation for treating virus myocaraitis, its preparation method and quality control method |
| CN103446410A (en) * | 2013-09-16 | 2013-12-18 | 管淑红 | Traditional Chinese medicine preparation for treating viral myocarditis |
| CN104225061A (en) * | 2014-09-30 | 2014-12-24 | 高清 | Traditional Chinese medicine for treating qi and yin deficiency type viral myocarditis |
| CN105362701A (en) * | 2015-12-22 | 2016-03-02 | 王伟 | Medicine for treating viral myocarditis |
| CN105521151A (en) * | 2014-09-29 | 2016-04-27 | 卢雨萍 | Preparation method of traditional Chinese medicine for treating myocarditis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1057924C (en) * | 1996-07-30 | 2000-11-01 | 马永凯 | Drug preparation for curing viral and many kinds of myocarditis, low fever and hypokalemia |
-
2004
- 2004-09-06 CN CNB2004100356474A patent/CN1302799C/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100349597C (en) * | 2005-11-14 | 2007-11-21 | 咸阳步长医药科技发展有限公司 | Chinese medicinal preparation for treating virus myocaraitis, its preparation method and quality control method |
| CN103446410A (en) * | 2013-09-16 | 2013-12-18 | 管淑红 | Traditional Chinese medicine preparation for treating viral myocarditis |
| CN103446410B (en) * | 2013-09-16 | 2015-02-18 | 于惠 | Traditional Chinese medicine preparation for treating viral myocarditis |
| CN105521151A (en) * | 2014-09-29 | 2016-04-27 | 卢雨萍 | Preparation method of traditional Chinese medicine for treating myocarditis |
| CN104225061A (en) * | 2014-09-30 | 2014-12-24 | 高清 | Traditional Chinese medicine for treating qi and yin deficiency type viral myocarditis |
| CN104225061B (en) * | 2014-09-30 | 2016-06-22 | 吴德美 | A kind of Chinese medicine treating type of deficiency of both QI and YIN viral myocarditis |
| CN105362701A (en) * | 2015-12-22 | 2016-03-02 | 王伟 | Medicine for treating viral myocarditis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1302799C (en) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100563690C (en) | A kind of medicine for the treatment of rheumatism, rheumatoid, puerperal exposure to wind, hyperosteogeny and disease of proplapse of lumbar intervertebral disc | |
| CN100502936C (en) | Chinese medicinal compound preparation for inhibiting tumor and resisting insenescence | |
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN1814208A (en) | Oral Chinese medicine for treating and preventing recurrence of uecerative stomatitis | |
| CN101366903B (en) | Traditional Chinese medicine composition for treating climacteric syndrome | |
| CN1302799C (en) | Oral Chinese medicinal composition for treating virus myocarditis | |
| CN1686500A (en) | Chinese medicinal preparation for treating breast impediment | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1223886A (en) | Pathogenic factor eliminating and healthy energy supporting anticancer medicine | |
| CN1051471C (en) | Drug composition for curing osteoporosis | |
| CN102205109B (en) | Chinese medicinal composition for treating rheumatism and application thereof | |
| CN1074292C (en) | Cancer treating medicine capsule | |
| CN1136939A (en) | Chinese drugs for curing hepatitis B | |
| CN101199667A (en) | Chinese medicine for treating leukemia, aplastic anemia | |
| CN100339093C (en) | Compound medicine for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1244335C (en) | Influenze resisting medicine | |
| CN1053381C (en) | Drug for promoting puerperal physiological recovery and curing postpartum disease | |
| CN1248722C (en) | Medicine for treating coronary heart disease and preparation method thereof | |
| CN100342879C (en) | Liver fibrosis treating prepn and its process | |
| CN1063077C (en) | Traditional Chinese medicine composition for lowering blood-lipid, and method for preparing same | |
| CN1076622C (en) | Chinese medicine for curing nephritis | |
| CN1309412C (en) | Medicine composition for treating AIDS and preparing method thereof | |
| CN100335111C (en) | Medicine for rheumatism and its preparation | |
| CN1504231A (en) | Medicine for tumour | |
| CN1189207C (en) | Chinese medicinal composition for improving human immunity and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANGHAI PHARMACEUTICAL GROUP QINGDAO GROWFUL PHAR Free format text: FORMER NAME: QINGDAO GUOFENG PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 266510, No. 18, Songhua River Road, Qingdao economic and Technological Development Zone, Shandong Patentee after: SHANGHAI PHARMACEUTICAL GROUP QINGDAO GUOFENG PHARMACEUTICAL CO.,LTD. Address before: 266510, No. 18, Songhua River Road, Qingdao economic and Technological Development Zone, Shandong Patentee before: Qingdao Growful Medicine Co.,Ltd. |
|
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20070307 |